Other activating factors of PAM pathway, including PIK3CA mutation, AKT1 mutation, AKT2 amplification, and loss of cancer suppressor gene PTEN, can also cause resistance to anti‐HER2 agents, such as trastuzumab and lapatinib [5, 28]. This evidence concerns the gene PIK3CA and cancer.